Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:4914 |
Name | esophagus adenocarcinoma |
Definition | An esophageal carcinoma that derives_from epithelial cells of glandular origin. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer esophageal cancer esophageal carcinoma esophagus adenocarcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
ERBB2 amp | Lapatinib | esophagus adenocarcinoma | no benefit | detail... |
Unknown unknown | IMR-1 | esophagus adenocarcinoma | not applicable | detail... |
ERBB2 amp FGFR2 amp | AZD4547 + Lapatinib | esophagus adenocarcinoma | sensitive | detail... |
ERBB2 over exp | Trastuzumab | esophagus adenocarcinoma | sensitive | detail... |
Unknown unknown | Nintedanib | esophagus adenocarcinoma | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01196390 | Phase III | Carboplatin + Paclitaxel + Trastuzumab Carboplatin + Paclitaxel | Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer | Active, not recruiting | USA | 0 |
NCT01307956 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab | Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer | Terminated | USA | 0 |
NCT01490749 | Phase I | Carboplatin + Cetuximab + Everolimus + Paclitaxel | Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer | Completed | USA | 0 |
NCT01526473 | Phase I | AVX901 | A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901 | Completed | USA | 0 |
NCT01747551 | Phase II | Aflibercept Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer | Completed | USA | 0 |
NCT01774851 | Phase II | MM-111 + Paclitaxel + Trastuzumab Paclitaxel + Trastuzumab | A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach | Terminated | USA | 0 |
NCT01913639 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Regorafenib | FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer | Completed | USA | 0 |
NCT02013154 | Phase I | DKN-01 + Paclitaxel | A Study of DKN-01 in Combination With Paclitaxel | Active, not recruiting | USA | 0 |
NCT02016534 | Phase II | AMG 337 | Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors | Terminated | USA | CAN | 16 |
NCT02024607 | Phase Ib/II | Capecitabine + Oxaliplatin Bevacizumab + Napabucasin Napabucasin + Regorafenib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Napabucasin Fluorouracil + Irinotecan + Leucovorin | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer | Completed | USA | CAN | 0 |
NCT02138929 | Phase I | Everolimus + Sonidegib | LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma | Completed | USA | 0 |
NCT02234180 | Phase II | Regorafenib | Study of Adjuvant Regorafenib vs Placebo in Patients With Node Positive Esophageal Cancer That Completed Pre-operative Therapy | Terminated | USA | 0 |
NCT02234596 | Phase II | Nintedanib | Nintedanib in Patients With Advanced Esophagogastric Cancer | Completed | USA | 0 |
NCT02241720 | Phase II | Regorafenib | Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers | Terminated | USA | 0 |
NCT02283359 | Phase I | Irinotecan + Selinexor | Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus | Terminated | USA | 0 |
NCT02317991 | Phase II | Nab-paclitaxel + Ramucirumab | Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer | Active, not recruiting | USA | 0 |
NCT02389751 | Phase I | Carboplatin Paclitaxel Ganetespib | A Study of Ganetespib in Combination With Chemoradiation | Completed | USA | 0 |
NCT02404441 | Phase Ib/II | Spartalizumab | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | Completed | USA | CAN | 12 |
NCT02460224 | Phase Ib/II | LAG525 Spartalizumab | Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | Completed | USA | CAN | 10 |
NCT02530437 | Phase Ib/II | Taladegib Carboplatin + Paclitaxel | A Phase 1B/2 Study of LY2940680 in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction | Active, not recruiting | USA | 0 |
NCT02559687 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180) | Active, not recruiting | 0 | |
NCT02564263 | Phase III | Pembrolizumab Docetaxel + Irinotecan + Paclitaxel | Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) | Active, not recruiting | 0 | |
NCT02638909 | Phase II | Ceritinib | Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies | Terminated | USA | 0 |
NCT02639065 | Phase II | Durvalumab | A Study of Durvalumab (MEDI4736) in Esophageal Cancer | Active, not recruiting | USA | 0 |
NCT02642809 | Phase I | Pembrolizumab | Pembrolizumab With Locally Delivered Radiation Therapy for the Initial Treatment of Metastatic Esophageal Cancers | Active, not recruiting | USA | 0 |
NCT02954536 | Phase II | Capecitabine + Cisplatin + Pembrolizumab + Trastuzumab | Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer | Active, not recruiting | USA | 0 |
NCT02962063 | Phase Ib/II | Carboplatin + Durvalumab + Paclitaxel | Durvalumab, an Anti-PD-L1 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer | Recruiting | USA | 0 |
NCT02971956 | Phase II | Pembrolizumab | A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer | Active, not recruiting | USA | 0 |
NCT02998268 | Phase II | Pembrolizumab Carboplatin + Paclitaxel | Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma | Recruiting | USA | 0 |
NCT03064490 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab | Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED) | Recruiting | USA | 0 |
NCT03122548 | Phase II | CRS-207 + Pembrolizumab | Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers | Terminated | USA | 0 |
NCT03132922 | Phase I | ADP-A2M4 cells | MAGE-A4c1032T for Multi-Tumor | Recruiting | USA | CAN | 0 |
NCT03165994 | Phase II | APX005M + Carboplatin + Paclitaxel | APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers | Recruiting | USA | 0 |
NCT03189719 | Phase III | Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Pembrolizumab | First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590) | Active, not recruiting | USA | CAN | 24 |
NCT03193918 | Phase I | Crenolanib + Paclitaxel + Ramucirumab | Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma | Completed | USA | 0 |
NCT03196232 | Phase II | Epacadostat + Pembrolizumab | Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer | Completed | USA | 0 |
NCT03313778 | Phase I | mRNA-4157 + Pembrolizumab mRNA-4157 | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603) | Recruiting | USA | 0 |
NCT03365791 | Phase II | LAG525 Spartalizumab | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | Completed | USA | 0 |
NCT03604991 | Phase II | Carboplatin + Paclitaxel Nivolumab Carboplatin + Nivolumab + Paclitaxel Ipilimumab + Nivolumab | Carboplatin, Paclitaxel and Radiation Therapy With or Without Nivolumab and Ipilimumab in Treating Participants With Esophageal and Gastroesophageal Junction Adenocarcinoma | Recruiting | USA | 0 |
NCT03610711 | Phase Ib/II | Nivolumab + Relatlimab Nivolumab | REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer (REACTION) | Recruiting | USA | 0 |
NCT03694249 | Phase II | Ifetroban sodium | Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence | Recruiting | USA | 0 |
NCT03733990 | Phase Ib/II | FP-1305 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Recruiting | USA | 5 |
NCT03783936 | Phase II | Avelumab + Trastuzumab Avelumab + Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab | Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas | Active, not recruiting | USA | 0 |
NCT03784326 | Phase I | Atezolizumab + Fluorouracil + Oxaliplatin | Atezolizumab, Oxaliplatin, and Fluorouracil in Treating Patients With Esophageal or Gastroesophageal Cancer | Recruiting | USA | 0 |
NCT03840967 | Phase II | Niraparib | A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma | Recruiting | USA | 0 |
NCT03997448 | Phase II | Abemaciclib + Pembrolizumab | Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149 | Active, not recruiting | USA | 0 |
NCT04060342 | Phase Ib/II | GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | Recruiting | USA | 1 |
NCT04089904 | Phase II | Pembrolizumab | Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma | Recruiting | USA | 0 |
NCT04111172 | Phase II | Ad5.F35-hGCC-PADRE | Phase 2A Study of Ad5.F35-hGCC-PADRE in Gastrointestinal Malignancies | Recruiting | USA | 0 |
NCT04137289 | Phase I | BI 905711 | A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers | Recruiting | USA | 3 |
NCT04152018 | Phase I | PF-06801591 + PF-06940434 PF-06940434 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Recruiting | USA | 0 |
NCT04171141 | Phase I | PF-07062119 PF-07062119 + unspecified PD-1 antibody PF-07062119 + unspecified VEGF antibody | Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors. | Recruiting | USA | 1 |
NCT04210115 | Phase III | Cisplatin + Fluorouracil + Pembrolizumab Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Cisplatin + Fluorouracil | Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) | Recruiting | USA | CAN | 23 |
NCT04391049 | Phase I | Carboplatin + OBP-301 + Paclitaxel | Testing the Addition of the Anti-cancer Viral Therapy Telomelysin to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery | Recruiting | USA | 0 |
NCT04430738 | Phase I | Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy for HER2+ Gastrointestinal Cancers | Recruiting | USA | 0 |
NCT04460937 | Phase I | Adavosertib | Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers | Recruiting | USA | 0 |
NCT04510285 | Phase II | Pembrolizumab + Trastuzumab Trastuzumab | Study of Pembrolizumab Plus Trastuzumab or Trastuzumab Alone After Surgery in Patients With Esophagogastric Tumors | Recruiting | USA | 0 |
NCT04594811 | Phase II | Nivolumab Nivolumab + NT-I7 | NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma | Recruiting | USA | 0 |
NCT04757363 | Phase II | Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin + Regorafenib | A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer | Recruiting | USA | 0 |